Reporter assays showed that CHIR-99021 solubility dmso the activation of LXRs significantly reduced the transcriptional activity of FOXM1 promoter. Electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assays demonstrated that LXRα but not LXRβ could

bind to an inverted repeat IR2 (-52CCGTCAcgTGACCT-39) in the promoter region of FOXM1 gene. Moreover, FOXM1 expression in liver tissues was also inhibited in the mice fed with LXRs agonists. Conclusion: Taken together, we conclude that LXRα but not LXRβ functions as a transcriptional repressor for the expression of FOXM1. The pathway “LXRα-FOXM1-Cyclin D1/B1” is a novel mechanism by which LXRs suppress the proliferation of HCC cells, suggesting that the pathway may be a novel target for the treatment of HCC. Key Word(s): 1. LXRs; 2. FOXM1; 3. proliferation, cycle; 4. HCC; Presenting Author: QIANGJIAN WANG Additional Authors: JUNLI LAO, XIONGWEN ZOU, YUAN HUANG Corresponding Author:

YUAN HUANG Affiliations: The Second Affiliated Hospital of Nanchang University; the first affiliated hospital, liaoning medical schoo Objective: To assess the therapeutic effect of metformin combined with reduced glutathione on patients with non-alcoholic fatty liver disease. HKI-272 cell line Methods: 150 patients with non-alcoholic fatty liver disease were randomly divided into three groups, control group, low-dose group and high-dose group, each is 50 patients. Patients in low-dose group were treated with

metformin Methisazone (250 mg tid) combined with reduced glutathione (0.1 g tid) and patients in high-dose group were treated with metformin (500 mg tid) combined with reduced glutathione (0.1 g tid), while in control group treated with metformin (250 mg tid) for consecutive 6 months. Liver function indexes (ALT, AST, r-GT) and lipid levels (CH, TG, HDL, LDL) were compared before and after treatment. Side-effect was also observed during the experiment. Results: The liver function indexes and lipid levels of three groups were all obviously changed compared with pretherapy at the end point. It of high-dose and low-dose groups were all changed than control group (P < 0.05). And no severe side-effects occurred during the experiment. Conclusion: Metformin combined with reduced glutathione is an effective and safe remedy for treatment of non-alcoholic fatty liver disease, and with the increase dosage of metformin, the therapeutic effect increased. Key Word(s): 1. NAFLD; 2. metformin; 3. reduced glutathione; Presenting Author: LI CHANGPING Additional Authors: HESHUANG YAN Corresponding Author: LI CHANGPING Affiliations: affliated hospital Objective: To investigate the role of hepatocyte apoptosis, related factors: Fas, FasL, Bcl-2, Bax proteins and Caspase-8 mRNA in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) in rats.